APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

Tuberculosis (TB) Diagnostics

Tuberculosis (TB) is an infectious disease usually caused by the bacterium Mycobacterium tuberculosis (MTB). Tuberculosis generally affects the lungs, but can also affect other parts of the body. Most infections do not have symptoms, in which case it is known as latent tuberculosis. About 10% of latent infections progress to active disease which, if left untreated, kills about half of those infected. The classic symptoms of active TB are a chronic cough with blood-containing sputum, fever, night sweats, and weight loss. The historical term "consumption" came about due to the weight loss. Infection of other organs can cause a wide range of symptoms.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Tuberculosis (TB) is an infectious disease usually caused by the bacterium Mycobacterium tuberculosis (MTB). Tuberculosis generally affects the lungs, but can also affect other parts of the body. Most infections do not have symptoms, in which case it is known as latent tuberculosis. About 10% of latent infections progress to active disease which, if left untreated, kills about half of those infected. The classic symptoms of active TB are a chronic cough with blood-containing sputum, fever, night sweats, and weight loss. The historical term "consumption" came about due to the weight loss. Infection of other organs can cause a wide range of symptoms.

Selected research

Market Outlook & Growth Opportunities

Global Tuberculosis (TB) Diagnostics Market Outlook and Growth Opportunities 2026

Report ID 173895680426 December 2025194 pages

Choose your research edition.

Industry ResearchTuberculosis (TB) Diagnostics Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Tuberculosis (TB) Diagnostics Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Tuberculosis (TB) Diagnostics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032196 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Tuberculosis (TB) Diagnostics Market Outlook and Growth Opportunities 2026194 pages · $4,250 USDMarket Analysis & ForecastGlobal Tuberculosis (TB) Diagnostics Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

Tuberculosis (TB) is an infectious disease usually caused by the bacterium Mycobacterium tuberculosis (MTB). Tuberculosis generally affects the lungs, but can also affect other parts of the body. Most infections do not have symptoms, in which case it is known as latent tuberculosis. About 10% of latent infections progress to active disease which, if left untreated, kills about half of those infected. The classic symptoms of active TB are a chronic cough with blood-containing sputum, fever, night sweats, and weight loss. The historical term "consumption" came about due to the weight loss. Infection of other organs can cause a wide range of symptoms.

Global Tuberculosis (TB) Diagnostics key players include Danaher, Roche, Thermo Fisher Scientific, BD, Abbott, etc. Global top five manufacturers hold a share about 33%.

APAC is the largest market, with a share over 40%, followed by Americas and Europe, both have a share about 40 percent.

Read the full market overview

In terms of product, Culture-based is the largest segment, with a share about 33%. And in terms of application, the largest application is Hospitals, followed by Diagnostic Laboratories.

This report provides an overview of the global Tuberculosis (TB) Diagnostics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Tuberculosis (TB) Diagnostics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Tuberculosis (TB) Diagnostics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Tuberculosis (TB) Diagnostics market.

Tuberculosis (TB) Diagnostics Segment by Company

Danaher

Roche

Thermo Fisher Scientific

BD

Abbott

Hologic

Qiagen

BioMerieux

Hain Lifescience

Oxford Immunotec

Tuberculosis (TB) Diagnostics Segment by Type

Culture-Based Diagnostics

Sputum Smear Microscopy

Rapid Molecular Diagnostics

Others

Tuberculosis (TB) Diagnostics Segment by Application

Diagnostic Laboratories

Hospitals

Tuberculosis (TB) Diagnostics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Tuberculosis (TB) Diagnostics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Tuberculosis (TB) Diagnostics key companies, revenue, market share, and recent developments.

3. To split the Tuberculosis (TB) Diagnostics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Tuberculosis (TB) Diagnostics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Tuberculosis (TB) Diagnostics significant trends, drivers, influence factors in global and regions.

6. To analyze Tuberculosis (TB) Diagnostics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Tuberculosis (TB) Diagnostics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Tuberculosis (TB) Diagnostics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Tuberculosis (TB) Diagnostics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Tuberculosis (TB) Diagnostics industry.

Chapter 3: Detailed analysis of Tuberculosis (TB) Diagnostics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Tuberculosis (TB) Diagnostics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Tuberculosis (TB) Diagnostics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Tuberculosis (TB) Diagnostics Industry Trends Table 2. Tuberculosis (TB) Diagnostics Industry Drivers Table 3. Tuberculosis (TB) Diagnostics Industry Opportunities and Challenges Table 4. Tuberculosis (TB) Diagnostics Industry Restraints Table 5. Global Tuberculosis (TB) Diagnostics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Tuberculosis (TB) Diagnostics Revenue Share by Company (2021-2026) Table 7. Global Tuberculosis (TB) Diagnostics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Tuberculosis (TB) Diagnostics Key Company Manufacturing Base & Headquarters Table 9. Global Tuberculosis (TB) Diagnostics Company, Product Type & Application Table 10. Global Tuberculosis (TB) Diagnostics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Tuberculosis (TB) Diagnostics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Culture-Based Diagnostics Table 15. Significant Companies of Sputum Smear Microscopy Table 16. Significant Companies of Rapid Molecular Diagnostics Table 17. Significant Companies of Others Table 18. Global Tuberculosis (TB) Diagnostics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Tuberculosis (TB) Diagnostics Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Tuberculosis (TB) Diagnostics Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Tuberculosis (TB) Diagnostics Sales Value Share by Type (2021-2026) Table 22. Global Tuberculosis (TB) Diagnostics Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Diagnostic Laboratories Table 24. Significant Companies of Hospitals Table 25. Global Tuberculosis (TB) Diagnostics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Tuberculosis (TB) Diagnostics Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global Tuberculosis (TB) Diagnostics Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global Tuberculosis (TB) Diagnostics Sales Value Share by Application (2021-2026) Table 29. Global Tuberculosis (TB) Diagnostics Sales Value Share by Application (2027-2032) Table 30. Global Tuberculosis (TB) Diagnostics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Tuberculosis (TB) Diagnostics Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global Tuberculosis (TB) Diagnostics Sales Value Share by Region (2021-2026) Table 33. Global Tuberculosis (TB) Diagnostics Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global Tuberculosis (TB) Diagnostics Sales Value Share by Region (2027-2032) Table 35. Global Tuberculosis (TB) Diagnostics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global Tuberculosis (TB) Diagnostics Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global Tuberculosis (TB) Diagnostics Sales Value Market Share by Country (2021-2026) Table 38. Global Tuberculosis (TB) Diagnostics Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global Tuberculosis (TB) Diagnostics Sales Value Market Share by Country (2027-2032) Table 40. Danaher Company Information Table 41. Danaher Business Overview Table 42. Danaher Tuberculosis (TB) Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. Danaher Tuberculosis (TB) Diagnostics Product Portfolio Table 44. Danaher Recent Development Table 45. Roche Company Information Table 46. Roche Business Overview Table 47. Roche Tuberculosis (TB) Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Roche Tuberculosis (TB) Diagnostics Product Portfolio Table 49. Roche Recent Development Table 50. Thermo Fisher Scientific Company Information Table 51. Thermo Fisher Scientific Business Overview Table 52. Thermo Fisher Scientific Tuberculosis (TB) Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Thermo Fisher Scientific Tuberculosis (TB) Diagnostics Product Portfolio Table 54. Thermo Fisher Scientific Recent Development Table 55. BD Company Information Table 56. BD Business Overview Table 57. BD Tuberculosis (TB) Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. BD Tuberculosis (TB) Diagnostics Product Portfolio Table 59. BD Recent Development Table 60. Abbott Company Information Table 61. Abbott Business Overview Table 62. Abbott Tuberculosis (TB) Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Abbott Tuberculosis (TB) Diagnostics Product Portfolio Table 64. Abbott Recent Development Table 65. Hologic Company Information Table 66. Hologic Business Overview Table 67. Hologic Tuberculosis (TB) Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Hologic Tuberculosis (TB) Diagnostics Product Portfolio Table 69. Hologic Recent Development Table 70. Qiagen Company Information Table 71. Qiagen Business Overview Table 72. Qiagen Tuberculosis (TB) Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Qiagen Tuberculosis (TB) Diagnostics Product Portfolio Table 74. Qiagen Recent Development Table 75. BioMerieux Company Information Table 76. BioMerieux Business Overview Table 77. BioMerieux Tuberculosis (TB) Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. BioMerieux Tuberculosis (TB) Diagnostics Product Portfolio Table 79. BioMerieux Recent Development Table 80. Hain Lifescience Company Information Table 81. Hain Lifescience Business Overview Table 82. Hain Lifescience Tuberculosis (TB) Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Hain Lifescience Tuberculosis (TB) Diagnostics Product Portfolio Table 84. Hain Lifescience Recent Development Table 85. Oxford Immunotec Company Information Table 86. Oxford Immunotec Business Overview Table 87. Oxford Immunotec Tuberculosis (TB) Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Oxford Immunotec Tuberculosis (TB) Diagnostics Product Portfolio Table 89. Oxford Immunotec Recent Development Table 90. Research Programs/Design for This Report Table 91. Authors List of This Report Table 92. Secondary Sources Table 93. Primary Sources List of Figures Figure 1. Tuberculosis (TB) Diagnostics Product Image Figure 2. Global Tuberculosis (TB) Diagnostics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Tuberculosis (TB) Diagnostics Market Size (2021-2032) & (US$ Million) Figure 4. Global Tuberculosis (TB) Diagnostics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Culture-Based Diagnostics Image Figure 8. Sputum Smear Microscopy Image Figure 9. Rapid Molecular Diagnostics Image Figure 10. Others Image Figure 11. Global Tuberculosis (TB) Diagnostics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Tuberculosis (TB) Diagnostics Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Tuberculosis (TB) Diagnostics Sales Value Share by Type (2021-2032) Figure 14. Diagnostic Laboratories Image Figure 15. Hospitals Image Figure 16. Global Tuberculosis (TB) Diagnostics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Tuberculosis (TB) Diagnostics Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global Tuberculosis (TB) Diagnostics Sales Value Share by Application (2021-2032) Figure 19. Global Tuberculosis (TB) Diagnostics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global Tuberculosis (TB) Diagnostics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America Tuberculosis (TB) Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 22. North America Tuberculosis (TB) Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe Tuberculosis (TB) Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 24. Europe Tuberculosis (TB) Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific Tuberculosis (TB) Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific Tuberculosis (TB) Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America Tuberculosis (TB) Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 28. South America Tuberculosis (TB) Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa Tuberculosis (TB) Diagnostics Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa Tuberculosis (TB) Diagnostics Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • Culture-Based Diagnostics
  • Sputum Smear Microscopy
  • Rapid Molecular Diagnostics
  • Others
Applications
  • Diagnostic Laboratories
  • Hospitals
Companies covered
  • Danaher
  • Roche
  • Thermo Fisher Scientific
  • BD
  • Abbott
  • Hologic
  • Qiagen
  • BioMerieux
  • Hain Lifescience
  • Oxford Immunotec

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Tuberculosis (TB) Diagnostics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Tuberculosis (TB) Diagnostics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Tuberculosis (TB) Diagnostics Market Dynamics
  1. 2.1 Tuberculosis (TB) Diagnostics Industry Trends
  2. 2.2 Tuberculosis (TB) Diagnostics Industry Drivers
  3. 2.3 Tuberculosis (TB) Diagnostics Industry Opportunities and Challenges
  4. 2.4 Tuberculosis (TB) Diagnostics Industry Restraints
3 Tuberculosis (TB) Diagnostics Market by Company
  1. 3.1 Global Tuberculosis (TB) Diagnostics Company Revenue Ranking in 2025
  2. 3.2 Global Tuberculosis (TB) Diagnostics Revenue by Company (2021-2026)
  3. 3.3 Global Tuberculosis (TB) Diagnostics Company Ranking (2024-2026)
  4. 3.4 Global Tuberculosis (TB) Diagnostics Company Manufacturing Base and Headquarters
  5. 3.5 Global Tuberculosis (TB) Diagnostics Company Product Type and Application
  6. 3.6 Global Tuberculosis (TB) Diagnostics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Tuberculosis (TB) Diagnostics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Tuberculosis (TB) Diagnostics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Tuberculosis (TB) Diagnostics Market by Type
  1. 4.1 Tuberculosis (TB) Diagnostics Type Introduction
  2. 4.1.1 Culture-Based Diagnostics
  3. 4.1.2 Sputum Smear Microscopy
  4. 4.1.3 Rapid Molecular Diagnostics
  5. 4.1.4 Others
  6. 4.2 Global Tuberculosis (TB) Diagnostics Sales Value by Type
  7. 4.2.1 Global Tuberculosis (TB) Diagnostics Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Tuberculosis (TB) Diagnostics Sales Value by Type (2021-2032)
  9. 4.2.3 Global Tuberculosis (TB) Diagnostics Sales Value Share by Type (2021-2032)
5 Tuberculosis (TB) Diagnostics Market by Application
  1. 5.1 Tuberculosis (TB) Diagnostics Application Introduction
  2. 5.1.1 Diagnostic Laboratories
  3. 5.1.2 Hospitals
  4. 5.2 Global Tuberculosis (TB) Diagnostics Sales Value by Application
  5. 5.2.1 Global Tuberculosis (TB) Diagnostics Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Tuberculosis (TB) Diagnostics Sales Value by Application (2021-2032)
  7. 5.2.3 Global Tuberculosis (TB) Diagnostics Sales Value Share by Application (2021-2032)
6 Tuberculosis (TB) Diagnostics Regional Value Analysis
  1. 6.1 Global Tuberculosis (TB) Diagnostics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Tuberculosis (TB) Diagnostics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Tuberculosis (TB) Diagnostics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Tuberculosis (TB) Diagnostics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Tuberculosis (TB) Diagnostics Sales Value (2021-2032)
  7. 6.3.2 North America Tuberculosis (TB) Diagnostics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Tuberculosis (TB) Diagnostics Sales Value (2021-2032)
  10. 6.4.2 Europe Tuberculosis (TB) Diagnostics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Tuberculosis (TB) Diagnostics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Tuberculosis (TB) Diagnostics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Tuberculosis (TB) Diagnostics Sales Value (2021-2032)
  16. 6.6.2 South America Tuberculosis (TB) Diagnostics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Tuberculosis (TB) Diagnostics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Tuberculosis (TB) Diagnostics Sales Value Share by Country, 2025 VS 2032
7 Tuberculosis (TB) Diagnostics Country-level Value Analysis
  1. 7.1 Global Tuberculosis (TB) Diagnostics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Tuberculosis (TB) Diagnostics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Tuberculosis (TB) Diagnostics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Tuberculosis (TB) Diagnostics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Tuberculosis (TB) Diagnostics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Tuberculosis (TB) Diagnostics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Tuberculosis (TB) Diagnostics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Danaher
  2. 8.1.1 Danaher Company Information
  3. 8.1.2 Danaher Business Overview
  4. 8.1.3 Danaher Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Danaher Tuberculosis (TB) Diagnostics Product Portfolio
  6. 8.1.5 Danaher Recent Developments
  7. 8.2 Roche
  8. 8.2.1 Roche Company Information
  9. 8.2.2 Roche Business Overview
  10. 8.2.3 Roche Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Roche Tuberculosis (TB) Diagnostics Product Portfolio
  12. 8.2.5 Roche Recent Developments
  13. 8.3 Thermo Fisher Scientific
  14. 8.3.1 Thermo Fisher Scientific Company Information
  15. 8.3.2 Thermo Fisher Scientific Business Overview
  16. 8.3.3 Thermo Fisher Scientific Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Thermo Fisher Scientific Tuberculosis (TB) Diagnostics Product Portfolio
  18. 8.3.5 Thermo Fisher Scientific Recent Developments
  19. 8.4 BD
  20. 8.4.1 BD Company Information
  21. 8.4.2 BD Business Overview
  22. 8.4.3 BD Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 BD Tuberculosis (TB) Diagnostics Product Portfolio
  24. 8.4.5 BD Recent Developments
  25. 8.5 Abbott
  26. 8.5.1 Abbott Company Information
  27. 8.5.2 Abbott Business Overview
  28. 8.5.3 Abbott Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Abbott Tuberculosis (TB) Diagnostics Product Portfolio
  30. 8.5.5 Abbott Recent Developments
  31. 8.6 Hologic
  32. 8.6.1 Hologic Company Information
  33. 8.6.2 Hologic Business Overview
  34. 8.6.3 Hologic Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Hologic Tuberculosis (TB) Diagnostics Product Portfolio
  36. 8.6.5 Hologic Recent Developments
  37. 8.7 Qiagen
  38. 8.7.1 Qiagen Company Information
  39. 8.7.2 Qiagen Business Overview
  40. 8.7.3 Qiagen Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Qiagen Tuberculosis (TB) Diagnostics Product Portfolio
  42. 8.7.5 Qiagen Recent Developments
  43. 8.8 BioMerieux
  44. 8.8.1 BioMerieux Company Information
  45. 8.8.2 BioMerieux Business Overview
  46. 8.8.3 BioMerieux Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2021-2026)
  47. 8.8.4 BioMerieux Tuberculosis (TB) Diagnostics Product Portfolio
  48. 8.8.5 BioMerieux Recent Developments
  49. 8.9 Hain Lifescience
  50. 8.9.1 Hain Lifescience Company Information
  51. 8.9.2 Hain Lifescience Business Overview
  52. 8.9.3 Hain Lifescience Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Hain Lifescience Tuberculosis (TB) Diagnostics Product Portfolio
  54. 8.9.5 Hain Lifescience Recent Developments
  55. 8.10 Oxford Immunotec
  56. 8.10.1 Oxford Immunotec Company Information
  57. 8.10.2 Oxford Immunotec Business Overview
  58. 8.10.3 Oxford Immunotec Tuberculosis (TB) Diagnostics Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Oxford Immunotec Tuberculosis (TB) Diagnostics Product Portfolio
  60. 8.10.5 Oxford Immunotec Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst